A real- world experience with asciminib in elderly CML-CP patients intolerant to previous
DOI:
https://doi.org/10.18203/2320-6012.ijrms20260266Keywords:
Chronic myeloid leukemia, Chronic phase, Asciminib, Tyrosine kinase inhibitor intolerance, Elderly patients, Comorbidities, Real-world evidence, Case reportAbstract
Tyrosine kinase inhibitors (TKIs) have transformed the management of chronic myeloid leukemia in chronic phase (CML-CP). However, long-term therapy is often limited by intolerance, adverse events, and quality of life (QOL) concerns. Asciminib, is the 1st and only approved BCR. ABL1 inhibitor that works by STAMP (Specifically Targeting the ABL Myristoyl Pocket), has demonstrated efficacy and tolerability in patients previously treated with ≥2 TKIs. We report two elderly CML-CP patients with intolerance to multiple TKIs who achieved sustained responses with asciminib. A 60-year-old woman with CML-CP, diabetes, hypertension, and CKD. After intolerance to Dasatinib and Nilotinib (due to recurrent pleural effusion), she was switched to Asciminib in March 2025. Since then, her leukemia remains under complete molecular control, and her overall condition is stable with manageable comorbidities. A 77-year-old male with CML (chronic phase, November 2022) presented with weight loss, anorexia, and fatigue. Initial TKIs (Nilotinib, Dasatinib, Imatinib) led to cytopenias/intolerance, but since June 2024 on Asciminib 80 mg OD, he has achieved deep molecular response (BCR-ABL 0.139% as of July 2025) and remains clinically stable with manageable cytopenias. These real-world cases highlight the clinical utility of asciminib in elderly, comorbid CML-CP patients who are intolerant to the previous TKIs. Asciminib provided durable molecular responses and superior tolerability, consistent with trial data, and represents a valuable therapeutic option in this challenging patient population.
Metrics
References
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–27. DOI: https://doi.org/10.1056/NEJMoa1609324
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709. DOI: https://doi.org/10.1002/ajh.25792
George B, Chan K H, Rios A. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy. Front oncol . 2024;14:1446517. DOI: https://doi.org/10.3389/fonc.2024.1446517
Hoch M, Huth F, Manley P W, Loisios-Konstantinidis I, Combes F P, Li Y F, et al. Clinical Pharmacology of Asciminib: A Review. Clin pharmacokinet. 2024;63(11):1513–28. DOI: https://doi.org/10.1007/s40262-024-01428-6
Minami Y, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, et al. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study. Int j hematol. 2024;120(3): 305–13. DOI: https://doi.org/10.1007/s12185-024-03805-0
Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A Phase 3, open-label, randomized study of asciminib vs bosutinib in CML after ≥2 prior TKIs (ASCEMBL). Blood. 2021;138(21):2031–41. DOI: https://doi.org/10.1182/blood.2020009984
Mauro MJ, Minami Y, Hochhaus A, Lomaia E, Voloshin S, Turkina A, et al. Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL. Blood Advances. 2025;9(16):4248-59. DOI: https://doi.org/10.1182/bloodadvances.2025016042
Kennedy J A, Hobbs G. Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making. Curr hematol malig rep. 2018;13(3):202-11. DOI: https://doi.org/10.1007/s11899-018-0449-7
Breccia M, Efficace F, Iurlo A, Luciano L, Abruzzese E, Gozzini A, et al. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. Expert opin drug saf. 2018;17(6):623–8. DOI: https://doi.org/10.1080/14740338.2018.1480719
Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. Clin Lymphoma Myeloma Leuk. 2017;17(2):78-82. DOI: https://doi.org/10.1016/j.clml.2016.09.012
Huang CE, Lee K D, Chang J J, Tzeng HE , Huang S H, Yu L H, et al. Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National Population-Based Cohort Study. The oncologist. 2024;29(1): e81–9. DOI: https://doi.org/10.1093/oncolo/oyad225
Alwadi M, Chiu M, Gupta G, Perusini MA, Kim DDH. Real-World Experience of Asciminib Treatment and Its Clinical Outcomes Including Cardiovascular (CV) Event-Free, Failure-Free Survival Associated with CV Comorbidity and Framingham CV Risk Score in Patients with Chronic Myeloid Leukemia. Blood. 2024;144(1): 6618. DOI: https://doi.org/10.1182/blood-2024-211439
Lang F, Pemberton-Whiteley Z, Clements J, Ruiz C, Rea D, Machadol L, et al. P668: chronic myeloid leukemia survey on unmet needs (cml sun): balancing tolerability and efficacy goals of patients and physicians through shared treatment decision-making. HemaSphere. 2023;7(1):e8318962. DOI: https://doi.org/10.1097/01.HS9.0000969576.83189.62
Downloads
Published
How to Cite
Issue
Section
